Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $72.00

Definium Therapeutics (NASDAQ:DFTX) had its price target raised by Wells Fargo & Company from $68.00 to $72.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

DFTX has been the topic of several other research reports. Wall Street Zen downgraded shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Royal Bank Of Canada reissued an “outperform” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Canaccord Genuity Group set a $58.00 price target on Definium Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Finally, Oppenheimer restated an “outperform” rating and set a $70.00 price objective on shares of Definium Therapeutics in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $62.14.

Definium Therapeutics Trading Down 2.9%

Shares of DFTX opened at $42.63 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. The firm has a 50 day simple moving average of $39.83 and a 200-day simple moving average of $26.82. Definium Therapeutics has a 1-year low of $8.70 and a 1-year high of $49.70. The stock has a market cap of $5.73 billion, a price-to-earnings ratio of -12.43 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Equities analysts forecast that Definium Therapeutics will post -2.81 EPS for the current fiscal year.

Insider Activity at Definium Therapeutics

In related news, insider Mark Sullivan sold 13,008 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the sale, the insider directly owned 320,571 shares of the company’s stock, valued at approximately $14,435,312.13. This trade represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brandi Roberts sold 3,013 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the sale, the chief financial officer owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. The trade was a 1.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 48,096 shares of company stock valued at $2,165,763 over the last three months. Insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

Several institutional investors have recently made changes to their positions in DFTX. Russell Investments Group Ltd. increased its holdings in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after acquiring an additional 3,020 shares during the last quarter. Caxton Associates LLP acquired a new position in Definium Therapeutics in the third quarter valued at $126,000. Mercer Global Advisors Inc. ADV grew its position in Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after acquiring an additional 2,079 shares during the period. Finally, Scientech Research LLC purchased a new stake in Definium Therapeutics during the third quarter valued at about $286,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported that its Phase 3 VOYAGE study of DT120 ODT in generalized anxiety disorder achieved its primary goals. The treatment produced a 5.4-point improvement on the HAM-A anxiety scale versus placebo, strengthening the case for DT120’s potential efficacy and supporting future regulatory and commercial plans. Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo
• Positive Sentiment: The positive clinical readout has increased confidence in additional DT120 trials and potentially supports the drug’s use across more than one indication. Investors are also watching for a further catalyst expected in September 2026. Definium Therapeutics Hits Phase 3 GAD Goals For DT120 ODT
• Positive Sentiment: Analysts raised their targets following the data: JonesTrading increased its target to $90 from $74 and maintained a Buy rating; Robert W. Baird raised its target to $75 from $57; Wells Fargo lifted its target to $72 from $68; and RBC raised its target to $66 from $57 while assigning an Outperform rating. These revisions indicate substantial perceived upside, although targets are not guarantees. Analyst price-target updates
• Positive Sentiment: Needham reportedly expects DFTX shares to rise, while recent analyst commentary broadly reflects optimism about DT120’s development prospects. Needham analyst outlook
• Neutral Sentiment: Near-term trading may remain volatile as investors assess the Phase 3 results, upcoming milestones, and expectations for third-quarter earnings. HC Wainwright Q3 earnings estimate
• Negative Sentiment: DFTX remains an unprofitable biotechnology company, and its latest reported quarter missed consensus EPS estimates. The stock’s large recent rally and elevated volatility could also encourage profit-taking despite the favorable trial news.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.